FDA initiates fast-track review process for psilocybin and methylone as mental health treatments
The FDA has moved to expedite its review of psilocybin and methylone, two psychedelic compounds, for potential mental health applications. The action follows a directive from the Trump administration. The fast-track designation is intended to accelerate the regulatory evaluation process for these substances.
22
Divergence score
This event sits in the top 25% of divergence this week. 5 outlets covered it, splitting into 4 framing camps across 3 bias groups.
4 camps
3 bias groups
The spectrum · how 4 outlets placed this story
LeftCenterRight
CNN
Reuters
The Hill
Reason
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
CNN emphasizes mental health treatme...
How each outlet covered it
Fact ledger · what actually happened, cross-checked